ASAH1 and intrahepatic cholangiocarcinoma: Furthermore, treatment with rolipram (10 μM), a cAMP‐specific phosphodiesterase inhibitor, showed increased AC activity, whereas SQ22536 (10 μM), an AC inhibitor, decreased AC activity in colonic ICC (Figure 4A, B, n = 4–7).